InvestorsHub Logo

Wingus37

06/06/18 2:36 PM

#22996 RE: finesand #22995

CYDY will be in dollar land soon enough. Jump on board! Train is getting ready to leave!

finesand

06/06/18 2:52 PM

#22997 RE: finesand #22995

Incomplete Summary of Scientists Involved ..

.. for our credibility witch hunt (o8>

Inside Scientists
- Paul J. Maddon, MD, Ph.D., Senior Science Advisor to CytoDyn, an inventor of PRO 140 and retired founder, Chairman, CEO and CSO of Progenics Pharmaceuticals, Inc

- Denis R. Burger, Ph.D., Vice Chairman and Chief Science Officer. (Our questionable position)

- Nader Pourhassan, Ph.D., CytoDyn’s President and Chief Executive Officer

Scientific Advisory Board
- David Hinrichs, Ph.D., is a research scientist at the Veterans Administration Medical Center in Portland, Oregon and Professor of Molecular Microbiology and Immunology at Oregon Health & Science University (OHSU). He received a B.S. in Biology from Mankato State and Ph.D. in Microbiology and Immunology from the University of Arizona.

- Patrick Iversen, Ph.D., is adjunct professor at Oregon State University and scientific founder and Chief Science Officer of LS Pharma, LLC., a biopharmaceutical company focused on the discovery and development of novel RNA-based therapeutics. Dr. Iversen earned a B.S. degree from Westminster College and Ph.D. in Biochemical Pharmacology and Toxicology from the University of Utah School of Medicine.

- Daniel Lindner, MD, Ph.D., is Director of Animal Tumor Core of the Taussig Cancer Institute at the Cleveland Clinic. He received a BS in biology from MIT, medical degree from Georgetown University, Ph.D. in microbiology from the Medical College of Wisconsin.

- Richard Pestell, MD, Ph.D., MB.BS, FRACP, FACP, FAAAS, MBA, FRS of Medicine, is President of the Pennsylvania Cancer and Regenerative Medicine Research Center and Distinguished Professor at the Baruch S. Blumberg Institute. He received a medical degree from the University of Western Australia, Ph.D. from the University of Melbourne and conducted postdoctoral research at the Harvard School of Medicine and Massachusetts General Hospital. He received his executive MBA from New York University Stern School of Business.

- David L. Porter, MD, is the Jodi Fisher Horowitz Professor of Leukemia Care Excellence and Director of Cell Therapy and Transplantation at the University of Pennsylvania. He received his medical degree from Warren Alpert Medical School of Brown University.

- Jonah Sacha, Ph.D., is associate professor at OHSU and has appointments in the Vaccine & Gene Therapy Institute and Oregon National Primate Research Center. He received his Ph.D. in Medical Microbiology & Immunology from the University of Wisconsin-Madison and B.S. in Biology from the University of Missouri-Columbia.

Researcher (incomplete)
- Kush Dhody, Dr., Vice President of Clinical Operations for Amarex Clinical Research. Dr. Dhody earned his Doctor of Medicine (MD equivalent) degree from the University of Pune in India, and his Master of Science in Clinical Research from Cranfield University in the UK. He has an ACRP certification as a Clinical Research Professional.

- Jeffrey M. Jacobson, MD Co-Director, Center for Translational AIDS Research; Appointed Professor of Medicine, Professor of Neuroscience and Professor in the Center for Neurovirology at the Lewis Katz School of Medicine at Temple University (LKSOM). Dr. Jacobson is a nationally and internationally-renowned expert in clinical research on HIV and other chronic viral infections.

- Jacob P. Lalezari, MD serves as Director of Quest Clinical Research and an Assistant Clinical Professor of Medicine at UCSF/Mount Zion Hosp HSV, Hepatitis B ital. Dr. Lalezari served as Co-Director of the HIV Clinical Research Center at Mt. Zion Medical Center and also at the University of California in San Francisco. He has been Member of HIV Scientific Advisory Board at Ardea Biosciences Inc., since February 2008. Since 1989, Dr. Lalezari has served as a Principal Investigator for Phase 1, 2, and 3 clinical studies of new therapies for viral diseases including HIV/AIDS, CMV, HPV,& C, Influenza, and RSV.

- Melanie A. Thompson, M.D., is founder and principal investigator of the AIDS Research Consortium of Atlanta (ARCA), one of the first non-profit community-based HIV/AIDS research centers in the United States and the primary resource for clinical research in Georgia. She is also a private practitioner in Atlanta and serves on the Georgia's State Task Force on AIDS. Dr. Thompson was recently appointed member of the National Institutes of Health Office of AIDS Research Advisory Council by Donna Shalala, U.S. Secretary of Health and Human Services. In addition, Dr. Thompson is a member of the steering committee for NIAID's Community Programs for Clinical Research on AIDS (CPCRA) and serves on its HIV Therapies Core Committee.

- Paul J. Maddon (see above)

PE Data Congratulations from
- Scott M. Hammer, MD, Harold C. Neu Professor and Chief of the Division of Infectious Diseases, Columbia University Medical Center/New York-Presbyterian Hospital

- Robert T. Schooley, MD, Professor of Medicine, Department of Infectious Diseases and Global Public Health, University of California, San Diego

Gold Seeker

06/06/18 10:31 PM

#23015 RE: finesand #22995

Finesand, one other thing to watch out for with a biotech is the type of journal they use for publication. There are a lot of publications out there that look respectable but use a pay to publish business plan.

Also, don't ever think that a scientific advisory is of great benefit. It is just a tool to make shareholders think their investment in a penny stock is safer. The people on those groups just sell their names and get shares to sell.

The best indicator is probably management who actually own shares and not just options. Believe it or not, Dr Moro used to convert options to shares, vote them and then convert them back to options.